Taraxasteryl palmitate
Taraxasteryl palmitate is a taraxasterol-type triterpene ester compound with antiemetic activity. Intralymphatic injection of 30 mg/kg and 100 mg/kg Taraxasteryl palmitate significantly inhibited vomiting in a copper sulfate-induced frog vomiting model, with vomiting latency extension rates of 116.9% and 120.0%, respectively. Taraxasteryl palmitate exerts its anti-reflex vomiting activity by prolonging the vomiting latency. Taraxasteryl palmitate can be used in the study of vomiting-related diseases (especially reflex vomiting). Taraxasteryl palmitate can be naturally extracted from the flowers of Inula linariaefolia.
For research use only. We do not sell to patients.
- CAS No.: 29803-90-5
- Formula: C46H80O2
- Molecular Weight:665.13
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 29803-90-5
-
Molecular Weight 665.13
-
Formula C46H80O2
-
SMILES
C[C@]12[C@]3([C@@](CC[C@]1([H])[C@@]4([C@@](C(C)([C@H](CC4)OC(CCCCCCCCCCCCCCC)=O)C)([H])CC2)C)([H])[C@]5([H])[C@@](CC3)(CCC([C@H]5C)=C)C)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Taraxasteryl palmitate Related Classifications
HY-N16985 Related Classifications
Powered by Bioz